Client Login Portal
    • addthis
    • link : Client Login
    • knowledge network
    • Practice Areas
    • Cases
    • About Us
    • News & Events
    • Our People
    • Knowledge Network
    • Contact Us
    Labaton Sucharow
    • addthis
    • link : Client Login
    • knowledge network
    • Practice Areas
    • Cases
    • About Us
    • News & Events
    • Our People
    • Knowledge Network
    • Contact Us
    • Practice Areas
    • Cases
    • About Us
    • News & Events
    • Our People
    • Contact Us
    • Knowledge Network
    • Client Login
    • Search
    • addthis
    • link : Client Login
    • knowledge network
    Labaton Sucharow
    • News & Events
      • Press Room
      • Published
      • Events
    • Digital Library
      • Videos
      • Podcasts
      • Webinars
    • News & Events
      • Press Room
      • Published
      • Events
      • The Liaison
    • Digital Library
      • Videos
      • Podcasts
      • Webinars

    Arizona Drug Company May Pay Illinois $4.5M Over Opioid Lawsuit

    Chicago Tribune
    August 4, 2017

    Michael P. Canty on states, taxpayers footing opioid-related expenses

    In a recent case, an Arizona drug company is preparing to settle a lawsuit brought on by the Illinois Attorney General, alleging the company pushed doctors to prescribe its opioid painkiller beyond its intended use.

    According to the lawsuit, the company sold nearly $12 million worth of the pain-killing and highly addictive drug fentanyl in Illinois between April 2012 and March 2015, and about 94 percent of those sales could be attributed to the state's top 10 prescribers of the drug.

    Illinois also accused Insys of marketing the drug to treat "breakthrough pain" rather than just "breakthrough cancer pain," though the drug may only be marketed for cancer pain. Company sales representatives also inserted themselves into the prescription-writing process, the state alleged.

    Such lawsuits are becoming increasingly common across the country as states and municipalities try to recoup some of the costs of the opioid epidemic hitting their streets and neighborhoods, said Labaton Sucharow partner Michael P. Canty, who has been consulting with a number of attorneys general's offices on whether to bring litigation over opioids.

    "Taxpayers should not be footing the bill, while at the same time, these companies that are alleged to be responsible for the opioid crisis are reaping record profits," said Canty, who also worked on opioid cases as a former federal prosecutor.

    "You may not know anybody who has an opioid drug addiction, but you're paying for the Narcan (taken for opioid overdoses), for the hospital stays, for the diversion courts, for children born with a chemical dependence on the drug," Canty said. "These are all costs being borne by states."

    Useful Links

    • Practice Areas
    • Cases
    • About Us
    • News & Events
    • Our People
    • Knowledge Center

    Our Locations

    footer-list-map_icon New York
    140 Broadway
    New York, NY 10005
    212-907-0700

    footer-list-map_icon Delaware
    222 Delaware Avenue, Suite 1510
    Wilmington, DE 19801
    302-573-2540

    Useful Links

    footer-list-map_icon Washington, D.C.
    1050 Connecticut Avenue, NW, Suite 500
    Washington, D.C. 20036
    212-907-0700

    Stay Connected

    • Facebook
    • Twitter
    • LinkedIn
    Labaton Sucharow
    • Attorney Advertising Disclaimer
    • Privacy Policy
    • Transparency in Coverage Rule
    • labaton.com
    • Labaton Sucharow All Rights Reserved 2023

    Attorney Advertising Disclaimer

    The materials appearing on this website are provided for informational purposes only and do not constitute legal advice. You should not take action based upon this information without consulting legal counsel. This site is not intended to create an attorney-client relationship. The hiring of a lawyer is an important decision that should not be based solely upon any single source of information, including advertising on this website. You may ask us to send you further information about us, and we urge you to review other sources of information about us.